Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02677324 · ClinicalTrials.gov registry record · Phase 2
Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT02677324 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 33 participants.
The verdict
NCT02677324, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
This research study is studying a targeted therapy as a possible treatment for relapsed or refractory Waldenstrom's Macroglobulinemia (WM). This study is using the study intervention ABT-199.
Interventions
- DRUG ABT199
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2016-05-09 |
| Est. Completion | 2022-02-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02677324
The ClinicalTrials.gov registry entry for NCT02677324 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ABT199 is the first listed.
NCT02677324 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02677324 about?
NCT02677324 is a clinical study titled "Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia". This research study is studying a targeted therapy as a possible treatment for relapsed or refractory Waldenstrom's Macroglobulinemia (WM). This study is using the study intervention ABT-199.
What is the current status of trial NCT02677324?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2016-05-09. Estimated completion is 2022-02-07.
What interventions are being tested in trial NCT02677324?
The interventions under investigation include: ABT199 (DRUG).
Who is sponsoring clinical trial NCT02677324?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.